Lilly Announces Results From SURMOUNT-1 Three-Year Study Of Tirzepatide, Showing Weekly Tirzepatide Injections Reduced Risk Of Progression To Type 2 Diabetes By 94% In Adults With Pre-Diabetes And Obesity
Author: Benzinga Newsdesk | August 20, 2024 06:52am